Introduction {#S1}
============

*Acinetobacter* spp. are increasingly raising serious concern because of their ability to rapidly develop resistance to a wide range of antimicrobials. Among these species, *Acinetobacter baumannii*, *Acinetobacter nosocomialis*, and *Acinetobacter pittii* are the most frequently isolated in hospitals globally ([@B46]). In the last few decades, relatively few studies have investigated non-*baumannii Acinetobacter* spp., likely owing to their low prevalence and resistant rates ([@B9]). However, non-*baumannii Acinetobacter* spp. are increasingly being found in clinical specimens and deserve more attention. This is true of *A. pittii*, previously called *Acinetobacter* genomic species three, which is increasingly found in food, clinical patients, and healthy individuals ([@B49]; [@B1]; [@B42]). Among *Acinetobacter* spp., *A. pittii* is the most commonly identified causative agent of nosocomial infections in patients hospitalized both in general ward and in intensive care units (ICUs) in Germany and is the most prevalent species identified among hospital-acquired *A. calcoaceticus*--*A. baumannii* (ACB) complex bloodstream isolates in France ([@B39]; [@B33]).

The ability of bacteria to rapidly acquire resistance poses crucial challenges to clinical treatment. We have previously shown that *A. baumannii* strains developed greater resistance with within-host evolution, thereby limiting the treatment options ([@B20]). Similar effects have also been observed for other species. For example, *Pseudomonas aeruginosa* showed rapid and large increases in resistance to carbapenem during antibiotic therapy that were likely due to *de novo* evolution and/or the selection of resistant subpopulations, indicating a potential risk for the rapid spread of antimicrobial resistance ([@B44]). Development of carbapenem resistance in sequential clinical isolates of *Raoultella ornithinolytica* carrying *bla*~OXA--232~ in a hospitalized patient during the course of ertapenem therapy was recently reported, highlighting the diagnostic challenges posed by strains producing inefficient types of carbapenemase ([@B22]). A more comprehensive understanding of resistance development would provide a molecular basis for improving the treatment of infections. However, to the best of our knowledge, no study to date has investigated the potential for the development of carbapenem resistance in *A. pittii*.

The emergence of carbapenem-resistant *A. pittii* has been reported worldwide. The rate of carbapenem resistance in *A. nosocomialis* and *A. pittii* isolates increased from 7.5% in 2010 to 22% in 2014 ([@B9]). Carbapenem resistance in *A. pittii* is mainly associated with the production of the carbapenem-hydrolyzing class D β-lactamases (CHDLs), such as OXA-23, OXA-58, OXA-72, OXA-143, and their variants ([@B50]; [@B15]; [@B43]; [@B9]). Besides, NDM-1-producing *A. pittii* isolates have also been reported in several cases ([@B49]; [@B18]; [@B32]; [@B14]). The emergence of carbapenem resistance in *A. pittii* reflects its ability to acquire and spread resistance genes, posing a challenge to the management of carbapenem-resistant non-*baumannii Acinetobacter* spp.

In this study, we characterized the *A. pittii* A1254 clinical isolate, which carries *bla*~OXA--499~, intrinsic *bla*~OXA--826~, and *bla*~ADC--221~, but is susceptible to imipenem and intermediate susceptible to meropenem. The carbapenem resistance profile of A1254 was different from that of another OXA-499 producing *A. pittii* strain, YMC2010/8/T346, even though the *bla*~OXA--499~ genetic environment was identical in the two strains, indicating the existence of phenotypic variation among OXA-499-producing *A. pittii* strains. Thus, we investigated the effect of imipenem exposure in the A1254 isolate to reveal its potential to develop carbapenem resistance.

Materials and Methods {#S2}
=====================

Bacterial Isolates and Culture Conditions {#S2.SS1}
-----------------------------------------

*Acinetobacter pittii* A1254 is a clinical strain isolated from the sputum sample of a patient with chronic obstructive pulmonary disease from the People's Hospital of Quzhou, Zhejiang Province, China, in 2010. The A1254 isolate was initially described in our previous study on the prevalence of carbapenem-hydrolyzing class D β-lactamase genes in *Acinetobacter* spp. isolates ([@B23]). *A. baumannii* reference strain ATCC 17978, *A. pittii* reference strain LMG1035, and *Escherichia coli* DH5α were employed for cloning experiments. The liquid medium used was Luria--Bertani (LB) broth (Oxford, United Kingdom). The medium was supplemented with imipenem (0.75 μg/ml) as required.

Antimicrobial Susceptibility Testing {#S2.SS2}
------------------------------------

The minimum inhibitory concentrations (MICs) of imipenem and meropenem were evaluated using the broth microdilution method according to the guidelines of the Clinical and Laboratory Standards Institute ([@B12]). Simultaneously, carbapenem MICs against A1254 were evaluated with Etest strips (bioMérieux, Marcy-l'Étoile, France). *E. coli* strain ATCC 25922 was used as quality control. The results were interpreted in accordance with the CLSI breakpoints.

Experimental Evolution Under Imipenem Selective Pressure {#S2.SS3}
--------------------------------------------------------

Four single colonies of the *A. pittii* A1254 ancestor strain were inoculated in LB broth supplemented with imipenem (0.75 μg/ml). This concentration was maintained throughout the experimental evolution. All the evolved lineages were passaged daily and independently with shaking (200 rpm) at 37°C. A 20-μl volume of overnight culture was collected and inoculated at a 1:100 dilution daily for 9 days, and the generations were calculated (∼6.64 generations a day) with reference to [@B31]. The four evolved populations were designated as CAB001, CAB002, CAB003, and CAB004. A different single colony was passaged daily in antibiotic-free LB broth as a blank control.

Whole-Genome Sequencing and Sequence Analysis {#S2.SS4}
---------------------------------------------

Genomic DNA of the four evolved populations (CAB001--CAB004) was extracted on day 9 using a QIAamp DNA Mini Kit (Qiagen, Valencia, CA, United States) following the manufacturer's recommendations. The quality and quantity of genomic DNA were determined by agarose gel electrophoresis and a NanoDrop spectrophotometer. A 300-bp library for Illumina paired-end sequencing was constructed from 5 μg of DNA using a Paired-End DNA Sample Prep Kit (Illumina, San Diego, CA, United States). The ancestor strain, *A. pittii* A1254, was sequenced by both long-read nanopore sequencing (Oxford Nanopore Technologies, Oxford, United Kingdom) and Illumina paired-end sequencing. Reads obtained from Illumina paired-end sequencing were used to correct the result of the nanopore sequencing using the Unicycler assembly pipeline ([@B47]). Paired-end sequence reads were assembled by SPAdes ([@B2]) and the *de novo* assemblies were subsequently annotated using the Prokka pipeline ([@B41]). The genome of A1254 was input to the CGE web server for detection of resistance genes (selected% ID threshold, 90%; selected minimum length, 60%)^[1](#footnote1){ref-type="fn"}^ ([@B52]). Breseq was used to find mutations in evolved populations compared with A1254 ([@B13]). Detected mutations were confirmed by PCR and Sanger sequencing. The primers used are listed in [Table 1](#T1){ref-type="table"}.

###### 

Primers used in the study.

  **Name**    **Primer sequence (5′--3′)**                            **Target gene/region**                                                  **Use**
  ----------- ------------------------------------------------------- ----------------------------------------------------------------------- ---------------------------------
  499AG F     CTTTCTGCAAACGATGTACT                                    *bla*~OXA--499~ upstream region                                         Verify detected mutations
  499AG R     GAGCCTTTTTCAGCAGTT                                                                                                              
  499-C-F     tgcggccgcaagcttgtcgacATGAAAAAATTTATACTTCCTATCTTCAGC\*   *bla*~OXA--499~ with (499P-C-F)/without (499-C-F) the upstream region   Recombinant vector construction
  499P-C-F    tgcggccgcaagcttgtcgacAAGCTCCATTTAACATAATGGGCG\*                                                                                 
  499/P-C-R   cagcaaatgggtcgcggatccTTATATAATCCCTAAATTTTCTAATG\*                                                                               
  826-C-F     tgcggccgcaagcttgtcgacATGACTAAAAAAGCTCTTTTCTTTGC\*       *bla*~OXA--826~ with (826P-C-F)/without (826-C-F) the upstream region   Recombinant vector construction
  826P-C-F    tgcggccgcaagcttgtcgacTGACCCAACCCTACCTAA\*                                                                                       
  826/P-C-R   cagcaaatgggtcgcggatccCTATAAAATACCGAGTTGTTCCAATCC\*                                                                              
  rpoB-Q-F    TACCTACAAGCGGTTTATCC                                    *rpoB*                                                                  RT-qPCR
  rpoB-Q-R    TGTTCGTCATCAAGGTGAAT                                    *rpoB*                                                                  RT-qPCR
  499-Q-F     AGCTACAACAACTGAGATTTTC                                  *bla*~OXA--499~                                                         RT-qPCR
  499-Q-R     CTTGTGTCCCGATGTTCATA                                    *bla*~OXA--499~                                                         RT-qPCR
  826-Q-F     CATAAAGCAACACCAACTGAA                                   *bla*~OXA--826~                                                         RT-qPCR
  826-Q-R     AACCAATATCAGCATTACCGA                                   *bla*~OXA--826~                                                         RT-qPCR

\* Lowercase letters indicate sequences for recombination, capital letters indicate primers for amplification.

Cloning and Transformation {#S2.SS5}
--------------------------

Fragments of *bla*~OXA--499~ with or without the promoter region were amplified from the wild-type *A. pittii* A1254 strain and the CAB009 and CAB010 mutants. Additionally, *bla*~OXA--826~ was also amplified, with or without its promoter region, but only from *A. pittii* A1254. The products were cloned into the *Bam*HI and *Sal*I-digested shuttle vector PYMAb2-Hyg^*r*^ using the ClonExpress^®^ II One Step Cloning Kit (Vazyme Biotech Co., Ltd., Nanjing, China) following the manufacturer's recommendations. Cloning was performed based on recombination. Briefly, PYMAb2-Hyg^*r*^ was digested with *Bam*HI and *Sal*I. Using the primer pairs shown in [Table 1](#T1){ref-type="table"}, PCR products comprising the target fragment flanked by the recombination sequences were obtained. Then, the linearized vector, purified PCR product, buffer, and enhanced recombinase (Exnase II) were mixed and incubated for 30 min, yielding the recombinant vectors. The recombinant vectors were transformed into *A. baumannii* ATCC 17978, *A. pittii* LMG1035, and A1254 by electroporation.

Quantitative Reverse Transcription PCR {#S2.SS6}
--------------------------------------

Quantitative reverse transcription PCR (RT-qPCR) was performed to measure the expression level of *bla*~OXA--499~ and *bla*~OXA--826~ in *A. pittii* A1254 and the CAB009 and CAB010 mutants submitted or not to imipenem selection. Total RNA was extracted using the RNeasy Mini Kit (Qiagen). RNA was reverse transcribed using random hexamers from Invitrogen (Carlsbad, CA, United States) and a reverse transcriptase from Takara Bio (Ôtsu, Japan), according to the manufacturer's instructions. Quantitative PCR was performed using the SYBR^®^ Premix Ex Taq^TM^ PCR Kit (Takara Bio) in a LightCycler 480 system (Roche Molecular Diagnostics, Rotkreuz, Switzerland). The Ct value of each sample was measured under the following conditions: 95°C for 5 min, followed by 40 amplification cycles at 95°C for 10 s, 52°C for 30 s, and 72°C for 30 s. The *rpoB* gene was used as an internal reference. The primers used are listed in [Table 1](#T1){ref-type="table"}. Triplicate samples were included in each run, and RT-qPCR was performed three times independently. Data were calculated based on the ΔΔCt method ([@B27]). Log~2~ fold change was used to evaluate the expression levels. Genes were identified as differentially expressed when the \|log~2~ fold change\| was \>1.5 ([@B48]). Differences in expression levels were assessed by two-tailed Student's *t*-tests. *P* \< 0.05 was considered significant.

RNA-Sequencing (RNA-Seq) {#S2.SS7}
------------------------

Three single colonies of each isolate (A1254, CAB009, and CAB010) were grown overnight in LB broth, diluted 1:100 in 100 ml of fresh LB medium, and harvested at the mid-log growth phase. The subsequent RNA extraction, library construction, and transcriptomic analysis were performed by staff at MAGIGENE (Guangzhou, China). RNA was extracted using TRIzol Reagent (Invitrogen) and treated with DNase. rRNA was removed using a Ribo-Zero rRNA Removal Kit (Illumina). Paired-end RNA-sequencing (RNA-Seq) libraries were constructed with the NEBNext^®^ Ultra II^TM^ Directional RNA Library Prep Kit (New England Biolabs, Inc., Ipswich, MA, United States) and sequenced on the Illumina HiSeq/MiSeq NextSeq platform (Illumina). Raw reads were filtered by fastp (version 0.19.7) ([@B10]). After quality control, the reads were compared with ribosomal RNA (rRNA) sequences in the Rfam database, and unmapped reads were used for subsequent analysis. Filtered reads were mapped to the A1254 genome (GenBank accession number: [CP049806](CP049806)-[CP049810](CP049810)) using Hisat2 (version 2.1.0) ([@B25]). The read counts were calculated by RSEM (version 1.3.1) ([@B26]). The output data were analyzed by edgeR (version 3.20.2) ([@B37]) and differences in the expression profiles of CAB009 and CAB010 were assessed by the expression ratio of each gene between the mutant and A1254. Genes were considered to be differentially expressed if their false discovery rate (FDR) was \<0.05 and the \|log~2~ fold change\| was \>1.5.

Results {#S3}
=======

Resistance Genes and the Genetic Environment of *bla*~OXA--499~ in *A. pittii* A1254 {#S3.SS1}
------------------------------------------------------------------------------------

Based on CLSI guidelines, *A. pittii* A1254 was susceptible to imipenem (MIC, 2 μg/ml) and intermediate susceptible to meropenem (MIC, 4 μg/ml) using the broth microdilution method. However, when determined by Etest strips, A1254 was susceptible to both imipenem (MIC, 1.5 μg/ml) and meropenem (MIC, 2 μg/ml), consistent with the result reported for when A1254 was first described ([@B23]). Although there was a one-fold difference, the MIC of meropenem evaluated by the two methods was the breakpoint for susceptibility and intermediate susceptibility, respectively. Because in this study we also employed the broth microdilution method to determine the MICs for the other strains, we adopted 4 μg/ml as the meropenem MIC against A1254 and determined the strain to be intermediate susceptible to meropenem.

A1254 carries four plasmids in addition to its 4,065,905-bp-long chromosome. We identified two oxacillinase (OXA) genes in A1254: *bla*~OXA--499~ and a variant of *bla*~OXA--500~. *bla*~OXA--499~ is a variant of *bla*~OXA--143~ identified in 2017 and is reported to confer resistance to carbapenem ([@B15]). The *bla*~OXA--500~ variant was submitted to National Center for Biotechnology information (NCBI) as a member of the OXA-213 family, and NCBI designated it as *bla*~OXA--826~. The phylogenetic tree of relative OXA variants is shown in [Figure 1](#F1){ref-type="fig"}. However, according to a recent study, it might be more appropriate to classify OXA-826 into the OXA-272-like family, which may be the intrinsic *A. pittii* OXA ([@B24]; [@B15]). We also found and submitted a variant of *bla*~ADC--25~, which was designated as *bla*~ADC--221~ by NCBI. *bla*~OXA--499~, *bla*~OXA--826~, and *bla*~ADC--221~ are all located on the chromosome. No other resistance genes were detected in A1254.

![Phylogenetic tree of relative OXA variants. The neighbor-joining tree was generated using CLC Main Workbench 8.5.1 (QIAGEN Bioinformatics).](fmicb-11-01134-g001){#F1}

We compared the genetic environment of *bla*~OXA--499~ in A1254 with that in the *A. pittii* isolate YMC2010/8/T346 in which *bla*~OXA--499~ was first identified (GenBank accession number: [CP017938](CP017938)). In the YMC2010/8/T346 isolate, *bla*~OXA--499~ is located within a 4,085-bp genomic fragment insertion consisting of a putative peptidase gene, *bla*~OXA--499~, and a TonB-dependent receptor plug domain, along with Xer C/D like recombination sites ([@B15]). The same fragment was identified in A1254 (100% identity).

Carbapenem-Resistant Evolved Populations and Mutations {#S3.SS2}
------------------------------------------------------

We serially passaged four populations independently for 9 days (∼6.64 generations per day). On day 9 (∼60 generations), we found that two of the four populations (CAB001 and CAB004) had become resistant to both imipenem and meropenem. For population 1, CAB001, the imipenem MIC increased to 32 μg/ml (a four-fold increase) and that of meropenem increased to 64 μg/ml (also a four-fold increase). For population 4, CAB004, the imipenem MIC increased to 8 μg/ml (a two-fold increase) while that of meropenem increased to 32 μg/ml (a three-fold increase).

To identify the mutations responsible for the increased MICs (at least two-fold) against CAB001 and CAB004, we compared the genome of each evolved population to the genome sequence of the A1254 ancestor strain. Mutations with a frequency \>70% are listed in [Supplementary Table S1](#TS1){ref-type="supplementary-material"}. Mutations occurring in population two (CAB002) and population three (CAB003) where the imipenem MIC showed only a one-fold increase (4 μg/ml) were excluded from further analysis. Therefore, the mutation in the promoter region of *bla*~OXA--499~, with a frequency of 100%, was the only mutation in CAB001 remaining for further analysis. A colony from the CAB001 population harboring this mutation was isolated and designated as CAB009.

Based on the evidence from CAB001, we suspected that the mutation in the promoter region of *bla*~OXA--499~ might be responsible for the increased carbapenem MICs in the population. To explore whether this mutation also existed in other populations, we isolated single colonies from CAB002--CAB004 and analyzed the sequence of the *bla*~OXA--499~ promoter region in each colony by PCR and Sanger sequencing. We identified another mutation in the promoter region of *bla*~OXA--499~ in a CAB004-derived colony, and we designated this mutant as CAB010. No mutations were found in the promoter region of *bla*~OXA--499~ in CAB002- and CAB003-derived colonies. Carbapenem MICs against the ancestor strain and the mutants are listed in [Table 2](#T2){ref-type="table"}.

###### 

Minimum inhibitory concentrations (MICs) for strains and transformants harboring recombinant vectors.

                                                            **MIC (μg/mL)**   
  --------------------------------------------------------- ----------------- -------
  *Acinetobacter pittii* A1254                              2                 4
  *A. pittii* CAB009                                        32                64
  *A. pittii* CAB010                                        8                 16
  *A. pittii* A1254 + pYMAb2_Hyg^*r*^                       2                 4
  *A. pittii* A1254 + pYMAb2_Hyg^*r*^:OXA499                2                 4
  *A. pittii* A1254 + pYMAb2_Hyg^*r*^:OXA499_P^*a*^         16                64
  *A. pittii* A1254 + pYMAb2_Hyg^*r*^:OXA499_P009^*b*^      32                128
  *A. pittii* A1254 + pYMAb2_Hyg^*r*^:OXA499_P010^*c*^      16                64
  *A. pittii* A1254 + pYMAb2_Hyg^*r*^:OXA826                2                 8
  *A. pittii* A1254 + pYMAb2_Hyg^*r*^:OXA826_P^*d*^         2                 8
  *Acinetobacter baumannii* ATCC 17978                      0.125             0.25
  *A. baumannii* ATCC 17978 + pYMAb2_Hyg^*r*^               0.125             0.5
  *A. baumannii* ATCC 17978 + pYMAb2_Hyg^*r*^:OXA499        0.125             0.5
  *A. baumannii* ATCC 17978 + pYMAb2_Hyg^*r*^:OXA499_P      16                128
  *A. baumannii* ATCC 17978 + pYMAb2_Hyg^*r*^:OXA499_P009   32                128
  *A. baumannii* ATCC 17978 + pYMAb2_Hyg^*r*^:OXA499_P010   32                128
  *A. baumannii* ATCC 17978 + pYMAb2_Hyg^*r*^:OXA826        0.25              0.25
  *A. baumannii* ATCC 17978 + pYMAb2_Hyg^*r*^:OXA826_P      0.25              0.25
  *A. pittii* LMG 1035                                      0.06              0.25
  *A. pittii* LMG 1035 + pYMAb2_Hyg^*r*^                    0.125             0.125
  *A. pittii* LMG 1035 + pYMAb2_Hyg^*r*^:OXA499             0.125             0.25
  *A. pittii* LMG 1035 + pYMAb2_Hyg^*r*^:OXA499_P           16                64
  *A. pittii* LMG 1035 + pYMAb2_Hyg^*r*^:OXA499_P009        64                128
  *A. pittii* LMG 1035 + pYMAb2_Hyg^*r*^:OXA499_P010        16                64
  *A. pittii* LMG 1035 + pYMAb2_Hyg^*r*^:OXA826             0.125             0.25
  *A. pittii* LMG 1035 + pYMAb2_Hyg^*r*^:OXA826_P           0.125             0.25

a

OXA499_P indicates

bla

OXA--

499

with its natural promoter cloned from A1254.

b

OXA499_P009 indicates

bla

OXA--

499

with its mutated promoter cloned from CAB009.

c

OXA499_P010 indicates

bla

OXA--

499

with its mutated promoter cloned from CAB010.

d

OXA826_P indicates

bla

OXA--

826

with its natural promoter cloned from A1254.

Thus, we identified two mutations in the promoter region of *bla*~OXA--499~ in CAB009 and CAB010 that might mediate carbapenem resistance. The promoter region of *bla*~OXA--499~ was defined based on a previous study ([@B50]). In the *A. pittii* CAB009 mutant from population one, we identified an A to G base substitution located one base upstream of the −10 region (position −14) ([Figure 2](#F2){ref-type="fig"}), yielding a 5′-TG-3′ motif in the extended −10 element. In the *A. pittii* CAB010 mutant from population 4, we identified a G to A base substitution upstream of the −35 hexamer (position −42) within the upstream (UP) element ([Figure 2](#F2){ref-type="fig"}).

![Locations of mutations in the carbapenem-resistant mutants CAB009 and CAB010 (boxed in blue). The start codon (boxed in red), the transcription initiation site (boxed in gray), and the −10 and −35 regions (boxed in green) are also indicated.](fmicb-11-01134-g002){#F2}

Relative Expression Levels of *bla*~OXA--499~ and *bla*~OXA--826~ in the Mutants {#S3.SS3}
--------------------------------------------------------------------------------

We next performed RT-qPCR to determine how the mutations affected the expression levels of *bla*~OXA--499~ and *bla*~OXA--826~. The results revealed that the expression level of *bla*~OXA--499~ increased significantly in CAB009, both in antibiotic-free LB broth (4.53 ± 0.19) and in LB broth supplemented with 0.75 μg/ml imipenem (4.68 ± 0.60). However, the difference between the two conditions was not significant (*P* = 0.6931) ([Figure 3A](#F3){ref-type="fig"}). In CAB010, a more significant increase in *bla*~OXA--499~ expression was observed under 0.75 μg/ml imipenem pressure (2.54 ± 0.15) compared with that in antibiotic-free LB broth (1.65 ± 0.25) (*P* = 0.006) ([Figure 3A](#F3){ref-type="fig"}). The higher expression level of *bla*~OXA--499~ in CAB009 might explain why it was more resistant to carbapenem than CAB010 ([Table 2](#T2){ref-type="table"}). Under imipenem selection pressure, there was a significant decrease in the expression level of *bla*~OXA--826~ in CAB010 but not CAB009 ([Figure 3B](#F3){ref-type="fig"}). However, based on the \|log~2~ fold-change\| threshold (\>1.5), only *bla*~OXA--499~ was identified as being differentially expressed in both CAB009 and CAB010. The RT-qPCR results indicated that *bla*~OXA--499~, but not *bla*~OXA--826~, played an important role in the development of carbapenem resistance. [Supplementary Table S2](#TS1){ref-type="supplementary-material"} depicts the fold changes normalized by *rpoB* and *bla*~OXA--826~, respectively.

![Log~2~ fold changes of **(A)** *bla*~OXA--499~ and **(B)** *bla*~OXA--826~ expression levels in mutants undergoing or not imipenem selection pressure. RT-qPCR analysis was performed with three biological and technical replicates per experiment. The 2^--ΔΔCt^ method was applied to calculate the fold change using *rpoB* as the reference gene and *Acinetobacter pittii* A1254 as the reference strain. The expression level was calculated as the log~2~ fold change. The bars represent means ± SD from triplicate biological repeats. The *P*-values (each mutant undergoing or not imipenem selection pressure) were determined by two-tailed Student's *t*-tests. \*\**P* \< 0.008; ns, not significant. IPM, imipenem.](fmicb-11-01134-g003){#F3}

The Results of Cloning and Transformation {#S3.SS4}
-----------------------------------------

To examine how the mutations affect carbapenem resistance, we amplified a sequence containing either *bla*~OXA--499~ alone or *bla*~OXA--499~ together with an upstream 114-bp segment that included the promoter region, from A1254, CAB009, and CAB010. The sequence of *bla*~OXA--826~ with or without an upstream segment (446 bp in total, comprising a putative promoter region) was amplified from A1254. All the amplified products were cloned into the pYMAb2-Hyg^*r*^ vector. The recombinant vectors were electroporated into *A. baumannii* ATCC 17978, *A. pittii* LMG 1035, and *A. pittii* A1254 for expression analysis. The strains carrying the corresponding recombinant vectors and their MICs are listed in [Table 2](#T2){ref-type="table"}.

The results were similar among the transformed strains with different genetic backgrounds. *bla*~OXA--499~ could not confer resistance to carbapenem without the upstream sequence. However, all the recombinant strains harboring *bla*~OXA--499~ with its original promoter became resistant to imipenem (MIC, 16 μg/ml) and meropenem (MIC, 64--128 μg/ml). Similar MICs were observed for recombinant strains harboring *bla*~OXA--499~ containing the promoter from CAB010 (P010), except for OXA-499_P010-transformed *A. baumannii* ATCC 17978, showing a one-fold higher imipenem MIC (32 μg/ml) than OXA-499_P-transformed strains (16 μg/ml). Among the *A. baumannii* and *A. pittii* strains, *bla*~OXA--499~ containing the CAB009 promoter (P009) conferred the highest imipenem MICs (32--64 μg/ml, one- to two-fold change) when compared with the recombinant strains harboring the original promoter. Increased meropenem MICs were only observed for *A. pittii* A1254 and LMG 1035 (128 μg/ml, one-fold).

Transcriptomic Analysis {#S3.SS5}
-----------------------

Differentially expressed genes between A1254 and CAB009 or CAB010 were identified based on the defined threshold. Overall, although the transcriptional patterns of CAB009 and CAB010 were different, *bla*~OXA--499~ was the only differentially expressed gene shared by the two mutants.

Eighty-eight differentially expressed genes were identified in CAB009 ([Table 3](#T3){ref-type="table"}). Among them, 82 were upregulated and six downregulated. A stress-induced protein-encoding gene G8E09_11565 showed a 5.22 log~2~ fold change higher expression level in CAB009 than in A1254, ranking first in the expression profile. This was followed by *bla*~OXA--499~, which showed a 4.70 log~2~ fold change higher expression level. We only identified three genes that were differentially expressed between CAB010 and A1254 ([Table 4](#T4){ref-type="table"}). The expression of *bla*~OXA--499~ was 2.04 log~2~ fold change higher in CAB010 than in A1254. G8E09_06800 (encoding a LysR family transcriptional regulator) and G8E09_06805 (encoding a type one glutamine amidotransferase domain-containing protein) showed 1.73 and 1.62 log~2~ fold change higher expression levels than A1254, respectively.

###### 

Differentially expressed genes in CAB009 compared with A1254.

  **Gene_ID**   **Description**                                                            **log~2~ FC^*a*^**   ***P*-value**   **FDR**
  ------------- -------------------------------------------------------------------------- -------------------- --------------- ---------
  G8E09_11565   Stress-induced protein                                                     5.22                 0.0000          0.0004
  G8E09_16100   OXA-143 family carbapenem-hydrolyzing class D beta-lactamase OXA-499       4.70                 0.0000          0.0000
  G8E09_11570   Hypothetical protein                                                       3.78                 0.0000          0.0000
  G8E09_11590   Damage-inducible protein CinA                                              3.59                 0.0000          0.0001
  G8E09_08710   Muconolactone Delta-isomerase                                              3.37                 0.0000          0.0000
  G8E09_09185   Hypothetical protein                                                       3.27                 0.0002          0.0095
  G8E09_12900   Benzoate 1,2-dioxygenase small subunit                                     3.21                 0.0000          0.0000
  G8E09_12895   Benzoate 1,2-dioxygenase large subunit                                     3.08                 0.0000          0.0000
  G8E09_10220   Hypothetical protein                                                       3.05                 0.0000          0.0000
  G8E09_07105   Hypothetical protein                                                       3.04                 0.0001          0.0043
  G8E09_12625   DUF4142 domain-containing protein                                          3.00                 0.0000          0.0000
  G8E09_09755   Hypothetical protein                                                       2.94                 0.0000          0.0001
  G8E09_11585   Iron-containing redox enzyme family protein                                2.92                 0.0001          0.0047
  G8E09_03990   BapA prefix-like domain-containing protein                                 2.85                 0.0000          0.0000
  G8E09_14955   Trehalose-phosphatase                                                      2.82                 0.0000          0.0000
  G8E09_08715   Muconate cycloisomerase                                                    2.69                 0.0000          0.0000
  G8E09_11610   Hypothetical protein                                                       2.68                 0.0000          0.0000
  G8E09_09795   Hypothetical protein                                                       2.66                 0.0000          0.0003
  G8E09_08150   SOS response-associated peptidase                                          2.66                 0.0000          0.0000
  G8E09_12315   Hypothetical protein                                                       2.63                 0.0000          0.0011
  G8E09_08605   MFS transporter                                                            2.60                 0.0000          0.0016
  G8E09_07245   DNA breaking-rejoining protein                                             2.58                 0.0000          0.0004
  G8E09_12905   Ring-hydroxylating dioxygenase ferredoxin reductase family protein         2.49                 0.0000          0.0000
  G8E09_10205   Hypothetical protein                                                       2.45                 0.0022          0.0488
  G8E09_08615   Amidase                                                                    2.45                 0.0010          0.0278
  G8E09_08625   IacB protein                                                               2.40                 0.0001          0.0048
  G8E09_14200   Hypothetical protein                                                       2.39                 0.0001          0.0044
  G8E09_08105   Hypothetical protein                                                       2.39                 0.0001          0.0061
  G8E09_08620   Acyl-CoA dehydrogenase                                                     2.39                 0.0004          0.0138
  G8E09_08600   OprD family porin                                                          2.37                 0.0000          0.0000
  G8E09_11790   Acyl-CoA dehydrogenase                                                     2.35                 0.0000          0.0013
  G8E09_14960   Trehalose-6-phosphate synthase                                             2.33                 0.0012          0.0314
  G8E09_12910   1,6-dihydroxycyclohexa-2,4-diene-1-carboxylatedehydrogenase                2.25                 0.0000          0.0009
  G8E09_10090   2-oxo acid dehydrogenase subunit E2                                        2.24                 0.0000          0.0012
  G8E09_07160   Type 1 glutamine amidotransferase                                          2.23                 0.0001          0.0076
  G8E09_14205   Non-heme iron oxygenase ferredoxin subunit                                 2.22                 0.0004          0.0151
  G8E09_08630   Nuclear transport factor 2 family protein                                  2.22                 0.0002          0.0092
  G8E09_09095   Type 1 glutamine amidotransferase domain-containing protein                2.19                 0.0000          0.0003
  G8E09_08650   Oxidoreductase                                                             2.15                 0.0000          0.0037
  G8E09_12920   Aromatic acid/H + symport family MFS transporter                           2.15                 0.0000          0.0000
  G8E09_08635   Aromatic ring-hydroxylating dioxygenase subunit alpha                      2.12                 0.0001          0.0073
  G8E09_10085   Dihydrolipoyl dehydrogenase                                                2.12                 0.0000          0.0018
  G8E09_11775   Enoyl-CoA hydratase                                                        2.10                 0.0006          0.0196
  G8E09_08705   Catechol 1,2-dioxygenase                                                   2.10                 0.0000          0.0008
  G8E09_00265   DUF1328 domain-containing protein                                          2.08                 0.0004          0.0151
  G8E09_09085   NAD(P)H-binding protein                                                    2.06                 0.0000          0.0000
  G8E09_08640   Hypothetical protein                                                       2.02                 0.0019          0.0437
  G8E09_10100   Thiamine pyrophosphate-dependent dehydrogenaseE1 component subunit alpha   2.02                 0.0001          0.0064
  G8E09_10095   Alpha-ketoacid dehydrogenase subunit beta                                  2.02                 0.0001          0.0065
  G8E09_14195   Aromatic ring-hydroxylating dioxygenase subunit alpha                      1.97                 0.0007          0.0205
  G8E09_08645   SDR family oxidoreductase                                                  1.94                 0.0002          0.0089
  G8E09_03110   Peroxiredoxin                                                              1.93                 0.0000          0.0003
  G8E09_07120   Molecular chaperone                                                        1.91                 0.0000          0.0014
  G8E09_07115   Spore coat protein U domain-containing protein                             1.90                 0.0006          0.0189
  G8E09_07200   Minor capsid protein                                                       1.88                 0.0016          0.0387
  G8E09_07955   Hypothetical protein                                                       1.85                 0.0000          0.0004
  G8E09_17600   Serine hydrolase family protein                                            1.83                 0.0012          0.0314
  G8E09_11605   Hypothetical protein                                                       1.81                 0.0005          0.0182
  G8E09_12810   Hypothetical protein                                                       1.79                 0.0006          0.0198
  G8E09_04225   Transglycosylase SLT domain-containing protein                             1.79                 0.0008          0.0229
  G8E09_09750   Hypothetical protein                                                       1.76                 0.0000          0.0024
  G8E09_14055   Hypothetical protein                                                       1.76                 0.0002          0.0089
  G8E09_06975   Hypothetical protein                                                       1.76                 0.0000          0.0014
  G8E09_11740   Enoyl-CoA hydratase                                                        1.76                 0.0003          0.0124
  G8E09_12805   LysE family transporter                                                    1.75                 0.0000          0.0004
  G8E09_08700   3-oxoacid CoA-transferase subunit A                                        1.74                 0.0001          0.0044
  G8E09_11745   SDR family oxidoreductase                                                  1.74                 0.0012          0.0318
  G8E09_12925   OprD family porin                                                          1.73                 0.0001          0.0064
  G8E09_10340   Hypothetical protein                                                       1.72                 0.0001          0.0067
  G8E09_19180   GlsB/YeaQ/YmgE family stress response membrane protein                     1.71                 0.0020          0.0463
  G8E09_01795   Hemerythrin domain-containing protein                                      1.71                 0.0008          0.0244
  G8E09_12835   Heavy-metal-associated domain-containing protein                           -1.70                0.0002          0.0091
  G8E09_07185   Hypothetical protein                                                       1.67                 0.0008          0.0229
  G8E09_18175   Flavodoxin family protein                                                  -1.65                0.0001          0.0044
  G8E09_12485   Hypothetical protein                                                       1.64                 0.0000          0.0033
  G8E09_08655   Flavin reductase family protein                                            1.63                 0.0000          0.0017
  G8E09_09715   Fimbria/pilus periplasmic chaperone                                        -1.61                0.0000          0.0012
  G8E09_12830   Copper-translocating P-type ATPase                                         -1.59                0.0001          0.0076
  G8E09_18170   DUF2938 domain-containing protein                                          -1.56                0.0001          0.0047
  G8E09_10080   Acetoin reductase                                                          1.56                 0.0003          0.0119
  G8E09_08695   CoA transferase subunit B                                                  1.56                 0.0001          0.0056
  G8E09_13275   3-(3-hydroxy-phenyl)propionate transporter MhpT                            1.56                 0.0003          0.0119
  G8E09_06835   3-hydroxyacyl-CoA dehydrogenase                                            1.56                 0.0002          0.0083
  G8E09_07815   Siderophore biosynthesis protein                                           -1.53                0.0005          0.0160
  G8E09_09965   CoA transferase subunit A                                                  1.52                 0.0013          0.0324
  G8E09_11795   MFS transporter                                                            1.51                 0.0000          0.0027
  G8E09_06685   Transglutaminase family protein                                            1.51                 0.0012          0.0307
  G8E09_17135   DMT family transporter                                                     1.50                 0.0001          0.0048

a

log

2

FC, log

2

fold change; FDR, false discovery rate.

###### 

Differentially expressed genes in CAB010 compared with A1254.

  **Gene_ID**   **Description**                                                        **log2FC^*a*^**   ***P*-value**   **FDR**
  ------------- ---------------------------------------------------------------------- ----------------- --------------- ---------
  G8E09_16100   OXA-143 family carbapenem-hydrolyzing class D beta-lactamase OXA-499   2.04              0.0000          0.0014
  G8E09_06800   LysR family transcriptional regulator                                  1.73              0.0000          0.0001
  G8E09_06805   type 1 glutamine amidotransferase domain-containing protein            1.62              0.0000          0.0014

a

log

2

FC, log

2

fold change; FDR, false discovery rate.

Discussion {#S4}
==========

*Acinetobacter pittii*, a member of the ACB complex, is increasingly recognized as a clinically important species following an improvement in identification methods that can better discriminate between *A. pittii* and *A. baumannii* ([@B49]). Here, we identified a carbapenem-non-resistant *A. pittii* clinical isolate, A1254, carrying *bla*~OXA--499~, intrinsic *bla*~OXA--826~, and *bla*~ADC--221~. OXA-499 was first identified in a carbapenem-resistant *A. pittii* clinical isolate, YMC2010/8/T346, recovered from a patient in South Korea in 2010 and reported in 2017 ([@B15]). A1254 was also isolated in 2010. YMC2010/8/T346 is susceptible to imipenem (MIC, 2 μg/ml) but resistant to meropenem (MIC, 16 μg/ml). We compared the 4,085-bp *bla*~OXA--499~ genetic environment between A1254 and YMC2010/8/T346 and found them to be identical. However, A1254 is susceptible to imipenem and intermediate-susceptible to meropenem based on the microbroth dilution method and even susceptible to meropenem when the Etest is used. The different MICs among *A. pittii* strains sharing an identical *bla*~OXA--499~ genetic environment indicate that *bla*~OXA--499~ expression might vary according to host and result in phenotypic variation, which might be due to the presence of additional related mechanisms that influence the phenotype.

However, when cloned into a vector, *bla*~OXA--499~ containing either the initial or mutated promoter could confer carbapenem resistance in host strains. A similar result was reported by [@B50], who found that, although OXA-255 did not confer carbapenem resistance to the *A. pittii* clinical isolate AF726, OXA-255-transformed *A. baumannii* ATCC 17978 and *A. pittii* SH024 were resistant to carbapenem. Similar to OXA-499, OXA-255 is also a member of the OXA-143 family and the 2,239-bp genomic fragment containing *bla*~OXA--255~ (GenBank accession number, [KC479325](KC479325)) in *A. pittii* AF726 is similar to that of *bla*~OXA--499~ in A1254 and YMC2010/8/T346 (99% identities). Considering that the genes were cloned into a shuttle vector and transformed into different *Acinetobacter* spp. strains by electroporation, we suspect that, apart from the genetic background of transformed strains, the introduction of the vector might also have influenced the expression level by providing multiple copies of the gene (dose effect), whereas in A1254, *bla*~OXA--499~ was located on the chromosome and as a single copy.

RT-qPCR and RNA-Seq results (log~2~ fold changes) for *bla*~OXA--499~ showed the same trend, although RNA-Seq data showed higher values. There was a significant difference in the number of differently expressed genes between CAB009 and CAB010 when compared with A1254. As CAB009 and CAB010 were isolated from two independently evolved populations, both mutants might harbor additional mutations besides the base substitutions in the promoter region of *bla*~OXA--499~. The different genotypes of CAB009 and CAB010 might explain the differences in the transcriptional profiles.

Subinhibitory concentrations of antibiotics can lead to gene expression changes and promote resistance ([@B4]; [@B11]). In this study, we demonstrated that a carbapenem-non-resistant strain, *A. pittii* A1254, which tends to be neglected in the clinical microbiology laboratory, can rapidly develop resistance to carbapenems when cultured in broth containing a low concentration of imipenem. Here, we evaluated the possible mechanisms underlying the increased expression level of *bla*~OXA--499~ by analyzing the sequence of the promoter region. The mutant CAB009 isolate harbored an A to G transition at position −14, causing a base combination transformation from 5′-TA-3′ to 5′-TG-3′ one base upstream of the −10 region. The importance of the 5′-TG-3′ motif in the extended -10 element has been demonstrated in *E. coli* ([@B36]; [@B7]; [@B29]). It is well known that the −10 and −35 regions are where RNA polymerase (RNAP) contacts, resulting in promoter recognition and initiation of transcription. There is an additional promoter element, the "extended −10 element," located one base upstream of the −10 region, with the major 5′-TG-3′ determinant positioned at −15/−14 with respect to the transcription start site ([@B29]). The 5′-TG-3′ motif is an important determinant of promoter activity ([@B45]; [@B36]; [@B7]). In our study, we suspect that it was the presence of the 5′-TG-3′ motif in the extended −10 element of the *bla*~OXA--499~ promoter of the CAB009 mutant that led to the increased expression of *bla*~OXA--499~, resulting in resistance to carbapenem. Another mutant, CAB010, exhibited a G to A transition at position −42, upstream of the −35 region. The UP element, located upstream of the −35 element (from approximately −40 to −60), can be recognized by RNAP and facilitates its initial binding as well as the subsequent steps in transcription initiation ([@B17]; [@B35]). A consensus UP element sequence consists almost exclusively of A and T residues and leads to increased promoter activity ([@B16]). For the wild-type strain, *A. pittii* A1254, the proximal site of the UP element, contains a near-perfect A tract from position −39 to −44, interrupted only by a G at position −42. Following the transition from G to A at position −42, the proximal site in the CAB010 mutant became a perfect A tract.

In this study, we employed whole-genome sequencing (WGS) to identify putative resistance genes in the ancestor strain and mutations in the populations obtained from the experimental evolution. For clinical use, comprehensive databases of known resistant genes and related mutations are necessary for the successful prediction of antibiotic-resistance phenotypes. It is known that the accumulation of one or more single-nucleotide variants (SNVs) in genes encoding antibiotic targets or transposon insertions can lead to antibiotic resistance ([@B40]). Published carbapenem resistance-related mechanisms in *A. pittii* include plasmid-borne *bla*~OXA--23~, *bla*~OXA--72~, or *bla*~OXA--58~; AbaR4-located *bla*~OXA--23~ on the chromosome; plasmid-borne class I integron containing *bla*~IMP--1~ ([@B30]; [@B42]; [@B9]); and a composite transposon containing *bla*~NDM--1~ ([@B49]). In addition, it has been proposed that *A. pittii* may be a resistance reservoir for the dissemination of NDM-1 ([@B5]; [@B21]). Overexpression of *bla*~OXA~ is typically mediated through promoters provided by insertion sequence (IS) elements, although OXA-40 and OXA-143 appear to be exceptions to this ([@B19]). The association with IS elements and frequent presence in plasmids highlight the potential of *bla*~OXA~ genes to spread within *Acinetobacter* spp. via transposition events and horizontal gene transfer ([@B51]). For OXA-143-like and OXA-40-like, *bla*~OXA--499~ is flanked by XerC/XerD-like recombinase sites in both *A. pittii* A1254 and YMC2010/8/T346, suggesting that this gene was acquired through recombination. This recombination system is exploited by mobile DNA elements to integrate into the host genome ([@B28]). A similar genetic context was also reported for other *A. pittii* isolates, in which the resistance gene was flanked by XerC/XerD-like recombinase sites ([@B8]; [@B38]; [@B6]). This suggests that *A. pittii* may be an important source of resistance genes and contribute to their dissemination among species.

Here, we report for the first time that mutations in the promoter region of *bla*~OXA--499~ can contribute to the development of carbapenem resistance, complementing other known carbapenem resistance mechanisms in *A. pittii*. Enhanced resistance to β-lactam resulting from promoter mutations has also been reported in *Staphylococcus aureus* ([@B3]). Additionally, loss of *pncA* expression due to promoter mutation conferred pyrazinamide resistance in multidrug-resistant tuberculosis isolates ([@B34]). This indicated that predicting resistance phenotypes based on the presence of resistance genes may be inaccurate in some circumstances; mutations on non-coding regions such as the promoter region should also be taken into consideration. One limitation of our study was that we failed to introduce a mutation in the wild-type A1254 strain due to technical restrictions. Moreover, we did not elucidate the specific mechanisms underlying the different carbapenem MICs between *A. pittii* strains harboring *bla*~OXA--499~.

In conclusion, to the best of our knowledge, our study represents the first investigation on the development of carbapenem resistance in an OXA-499-harboring, but carbapenem-non-resistant, *A. pittii* isolate. The genetic environment of *bla*~OXA--499~ was identical to that of a previously reported carbapenem-resistant *A. pittii* strain, indicating the existence of phenotypic variation in OXA-499-producing strains. We demonstrated that carbapenem-non-resistant *A. pittii* A1254 could become resistant to carbapenem under imipenem selective pressure and that a single-base substitution in the promoter region of *bla*~OXA--499~ contributed to the carbapenem-resistance phenotype. This highlights the need to monitor the potential development of carbapenem resistance when treating infections caused by non-resistant strains. The potential risk of resistance development requires that more attention be paid to the type, courses, and doses of antibiotics prescribed.
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